{ "Phase 3 Study of CGT9486 + Sunitinib for Advanced GIST", "This Phase 3 study is testing a new combination treatment, CGT9486 and sunitinib, for people with advanced gastrointestinal stromal tumors (GIST). Researchers want to see how well this combination works compared to sunitinib alone. The study will also look at how CGT9486 and sunitinib interact in the body. You may be eligible if you have locally advanced, metastatic (spread to other parts of the body), or unresectable GIST. The study aims to enroll about 482 participants and will measure drug levels in the body as a primary goal.", "design": "This is an open-label (you and your doctors will know which treatment you are receiving), international, multi-part Phase 3 study involving approximately 482 participants.", "commitments": "Participants will receive CGT9486 and/or sunitinib orally until study stopping rules are met. Some participants will also receive a single dose of midazolam on Day 1 and Day 16.", "compensation": "Not stated in the trial record.", "follow_up": "Drug levels (Cmax and AUC) will be measured at 14 or 16 days, but overall follow-up duration is not specified.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.